Metropolitan Life Insurance CO Amylyx Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$27.71 - $40.93 $6,955 - $10,273	-251 Reduced 7.97%	2,899 $85,000
Q4 2022 Jun 14, 2023	BUY	$29.75 - $39.26 $7,467 - $9,854	251 Added 8.66%	3,150 $116 Million
Q4 2022 Mar 30, 2023	BUY	$29.75 - $39.26 $28,054 - $37,022	943 Added 42.73%	3,150 $116,000
Q4 2022 Feb 15, 2023	BUY	$29.75 - $39.26 $28,054 - $37,022	943 Added 42.73%	3,150 $116,000
Q3 2022 Jun 14, 2023	SELL	$17.15 - $30.92 $11,867 - $21,396	-692 Reduced 23.87%	2,207 $62.1 Million
Q3 2022 Mar 30, 2023	BUY	$17.15 - $30.92 $24,215 - $43,659	1,412 Added 177.61%	2,207 $61,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $24,215 - $43,659	1,412 Added 177.61%	2,207 $62,000
Q2 2022 Jun 20, 2023	SELL	$6.85 - $19.93 $14,412 - $41,932	-2,104 Reduced 72.58%	795 $15,000
Q1 2022 Jun 20, 2023	SELL	$12.85 - $32.9 $27,036 - $69,221	-2,104 Reduced 72.58%	795 $10,000
Q1 2022 Mar 30, 2023	SELL	$12.85 - $32.9 $30,261 - $77,479	-2,355 Reduced 74.76%	795 $10,000
Q1 2022 May 12, 2022	BUY	$12.85 - $32.9 $10,215 - $26,155	795 New	795 $10,000

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.